Asia Pacific Healthcare Monitor Report Series
About this Report Series: FrontierView's Asia Pacific Healthcare Monitor report series dives deep into the top current market access and reimbursement trends in the APAC region, while providing an overview of other developments impacting Asia's healthcare ecosystem - every single month. Click on the Product Details tab for an Executive Summary and...
About this Report Series:
FrontierView's Asia Pacific Healthcare Monitor report series dives deep into the top current market access and reimbursement trends in the APAC region, while providing an overview of other developments impacting Asia's healthcare ecosystem - every single month.
Click on the Product Details tab for an Executive Summary and full Table of Contents from the latest report or click Request a Sample to download a complete report from a few months ago to see exactly how the report is structured before you buy.
You have two options to purchase this report:
- Purchase a copy of the most recent report ($349/report)
- Purchase 12-months of access ($249/report at a 20+% discount) - strongly recommended if you're monitoring the region on an ongoing basis
Money Back Guarantee: We are so confident in the quality of our analysis and forecasts, that all products purchased on this site are backed by a 100% money back guarantee.
What do you have to lose? Click the Add to Cart button to start our simple 3-step checkout process. We're standing to answer any questions that may come up along the way - simply use the chat box at the bottom of this screen.
As countries move into the endemic phase of COVID, a challenge facing healthcare systems across the region is the backlog of elective procedures. No country in Asia has developed an overarching strategy to address the backlog issue, and the current bottleneck is the lack of financing and capacity, especially the shortage of healthcare professionals.
Countries such as Australia, Malaysia, and the Philippines are struggling to find qualified healthcare professionals. Meanwhile, pricing pressure persists given rising inflation, supply chain bottlenecks, and geopolitical risks. In China, it is expected that biologics will be included in future VBP. In Japan, fierce debate on drug pricing continues ahead of the 2022 Honebuto.
All these challenges will put stress on payers, which may further bolster more aggressive localization measures, coverage expansion, price controls, and digital health expansions. For instance, the Indonesian government is strengthening its commitment to localization of medical products. Companies should expect continued growth in healthcare demand and continued attention to backlogs.Table of Contents
- Executive Summary
- Markets in Focus
- South Korea